[go: up one dir, main page]

MX2018011348A - Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. - Google Patents

Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.

Info

Publication number
MX2018011348A
MX2018011348A MX2018011348A MX2018011348A MX2018011348A MX 2018011348 A MX2018011348 A MX 2018011348A MX 2018011348 A MX2018011348 A MX 2018011348A MX 2018011348 A MX2018011348 A MX 2018011348A MX 2018011348 A MX2018011348 A MX 2018011348A
Authority
MX
Mexico
Prior art keywords
compositions
prevent
same
treat diseases
natural extracts
Prior art date
Application number
MX2018011348A
Other languages
English (en)
Other versions
MX421795B (es
Inventor
Brian Reid Christopher
T Collins Que
Original Assignee
Brian Reid Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brian Reid Christopher filed Critical Brian Reid Christopher
Publication of MX2018011348A publication Critical patent/MX2018011348A/es
Publication of MX421795B publication Critical patent/MX421795B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a una composición para reducir la expresión de miR-3120 en una célula o tejido de un sujeto, que comprende al menos un aceite o extracto seleccionados a partir de un grupo que comprende un extracto o aceite de naranja, incienso y cannabis. Un método para reducir la expresión de miR-3120 en una célula o tejido de un sujeto que comprende administrar al sujeto una composición que comprende al menos un aceite o extracto seleccionado a partir del grupo que comprende un aceite o extracto de naranja, incienso y cannabis.
MX2018011348A 2016-03-18 2017-05-18 Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades MX421795B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662390081P 2016-03-18 2016-03-18
US201662390438P 2016-03-29 2016-03-29
PCT/US2017/033234 WO2017161387A1 (en) 2016-03-18 2017-05-18 Compositions of natural extracts and use thereof in methods for preventing or treating diseases

Publications (2)

Publication Number Publication Date
MX2018011348A true MX2018011348A (es) 2019-07-12
MX421795B MX421795B (es) 2025-03-14

Family

ID=59850464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011348A MX421795B (es) 2016-03-18 2017-05-18 Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades

Country Status (6)

Country Link
US (1) US20190224193A1 (es)
BR (1) BR112018068986B1 (es)
IL (1) IL261884B (es)
MX (1) MX421795B (es)
WO (1) WO2017161387A1 (es)
ZA (1) ZA201806128B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468530A4 (en) 2016-06-10 2020-03-11 Clarity Cosmetics Inc. NON-COMEDOGEN FORMULA FOR HAIR AND SCALP CARE AND METHOD FOR USE
JP2019524655A (ja) 2016-06-29 2019-09-05 キャンサイエンス イノベーションズ インコーポレーテッドＣａｎｎｓｃｉｅｎｃｅ Ｉｎｎｏｖａｔｉｏｎｓ Ｉｎｃ． 脱炭酸大麻樹脂、その使用、及びそれを製造する方法
US11318179B2 (en) * 2017-06-20 2022-05-03 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
CN111050758A (zh) * 2017-09-28 2020-04-21 凯诺比生长公司 食用大麻素组合物
KR101959404B1 (ko) * 2017-11-09 2019-03-21 한국콜마주식회사 변색내성이 우수한 조합향료 함유 화장료 조성물
WO2019104291A1 (en) * 2017-11-27 2019-05-31 La'au Pono Combination of granulated dried botanical extract powder for symptom relief
CA3092802A1 (en) * 2018-03-05 2019-09-12 Laila Nutraceuticals Synergistic herbal compositions for the treatment of obesity and overweight
CN108796065B (zh) * 2018-06-26 2020-08-04 青岛泱深生物医药有限公司 Fam127a在妊娠疾病中的应用
US11026897B2 (en) * 2018-08-10 2021-06-08 Metagenics, Inc. Composition of curcumagalactomannoside and hops extract
US20200103396A1 (en) * 2018-09-27 2020-04-02 T. Que COLLINS Deuterium depletion measurement
WO2020109965A1 (en) * 2018-11-26 2020-06-04 Offhealth S.P.A. Collyrium containing citrus extract in liposomal form
JP2022534981A (ja) * 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
WO2021030679A2 (en) * 2019-08-14 2021-02-18 University Of Louisville Research Foundation, Inc. Compositions and methods for diagnosis and treatment of metabolic diseases and disorders
US12397030B2 (en) 2019-12-23 2025-08-26 Metagenics LLC Polyphenol compositions and uses thereof
CN111053761B (zh) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 一种吸入用双膦酸类药物及其制备方法及其在慢性阻塞性肺疾病的用途
CN111514311B (zh) * 2020-04-15 2023-01-31 郑州大学第一附属医院 共载阿霉素和si-PVT1的靶向外泌体及其制备和抗骨肉瘤应用
CA3181178A1 (en) * 2020-05-06 2021-11-11 Regeneron Pharmaceuticals, Inc. Kelch domain containing 7b (klhdc7b) variants and uses thereof
WO2021255464A1 (en) * 2020-06-17 2021-12-23 Norman Hahn Nutraceutical composition
CN111778340B (zh) * 2020-08-21 2022-08-30 河北医科大学第二医院 一种用于早期宫颈癌诊断的生物标志物
US20220054578A1 (en) * 2020-08-24 2022-02-24 Life Outside, LLC Composition and method for oral supplement repelling biting insects
CN112322746B (zh) * 2020-09-24 2022-03-18 浙江大学 Snhg9基因在细胞机械应力检测中的应用及试剂盒
CN113057940B (zh) * 2021-03-24 2022-08-19 贵州医科大学 1,8-桉叶油素乳剂及其制备方法
US20230085607A1 (en) * 2021-09-16 2023-03-16 Therapeutic Solutions International, Inc. Ivermectin compositions for treatment of covid-19
CN114225011B (zh) * 2021-12-31 2024-04-12 宁夏医科大学总医院 一种用于预防和治疗gsm的复合制剂及其应用
CN114469909A (zh) * 2022-01-25 2022-05-13 中国医学科学院药用植物研究所 姜黄素在制备治疗arl8a和/或arl8b蛋白高表达肿瘤的药物中的用途
US12458623B2 (en) * 2022-03-18 2025-11-04 Cytosolve, Inc. Low-grade inflammation compositions
CN114732785A (zh) * 2022-04-14 2022-07-12 辰欣药业股份有限公司 一种大蒜素注射液及其制备方法
AU2023286621A1 (en) 2022-06-21 2025-01-09 Lanzatech, Inc. Microorganisms and methods for the continuous co-production of tandem repeat proteins and chemical products from c1-substrates
JP2025525381A (ja) 2022-06-21 2025-08-05 ランザテク，インコーポレイテッド Ｃ１基質からの高価値の特殊タンパク質及び化学産物の連続共産生のための微生物及び方法
US12129503B2 (en) 2022-08-10 2024-10-29 Lanzatech, Inc. Carbon sequestration in soils with production of chemical products
EP4593859A1 (en) * 2022-09-28 2025-08-06 Eresina, LLC Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation
EP4593883A1 (en) * 2022-09-29 2025-08-06 Muhammed Majeed Compositions for the management of hirsutism
US12011420B2 (en) 2022-10-12 2024-06-18 Epitop, Inc. Compositions and methods for treatment of microbial infections
US20240216459A1 (en) * 2022-12-28 2024-07-04 Access Business Group International Llc Composition for preventing and/or ameliorating menstrual cycle symptoms and/or discomforts, and methods of producing and using the same
EP4642471A1 (en) * 2022-12-28 2025-11-05 Immune & Genetics Protocols Llc Plant hydroethanolic extracts and uses thereof
WO2024144610A1 (en) * 2022-12-28 2024-07-04 Istanbul Medipol Universitesi Teknoloji Transfer Ofisi Anonim Sirketi Nasal drop formulations in the form of in-situ gel comprising herbal essential oil combinations
WO2024141931A1 (en) * 2022-12-28 2024-07-04 O Sigma Cell And Genetic Llc Plant hydroethanolic extracts
US12281344B2 (en) 2023-06-05 2025-04-22 Lanzatech, Inc. Integrated gas fermentation
WO2024253883A1 (en) 2023-06-05 2024-12-12 Lanzatech, Inc. Integrated gas fermentation and carbon black processes
US12251464B1 (en) 2024-05-20 2025-03-18 Earth To Malibu, LLC Compositions and methods for sunless tanning
CN118593456A (zh) * 2024-05-21 2024-09-06 北京中医药大学东直门医院 Nkt在防治急性心衰中的应用
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
CN120442610B (zh) * 2025-07-14 2025-10-28 北京化工大学 β-喜马雪松烯合酶突变体及其产物雪松醇的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0761931A (ja) * 1993-08-25 1995-03-07 Nippon Zeon Co Ltd 癌転移抑制剤
JP2003504321A (ja) * 1999-07-08 2003-02-04 オーランド・ハン リポソーム被包カンナビノイドの肺送達
TWI293878B (en) * 2000-06-30 2008-03-01 Taipei Veterans General Hospital A composition comprising a mevalonate-reducing compound for sensitizing cancer cells to cancer therapies and kits comprising said composition and an anti-cancer agent
US6534540B2 (en) * 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
EP1575563B1 (en) * 2002-12-19 2007-02-14 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
JP2004217610A (ja) * 2003-01-15 2004-08-05 Internatl Scient:Kk 重水素減少水（スーパーライトウォーター）の生理食塩水による癌、糖尿病、白血病、不眠症の治療および若返り、細胞の活性化、免疫細胞の増加の促進
JP2007022978A (ja) * 2005-07-20 2007-02-01 Hiroshi Nojima がん自然転移抑制剤
US8927019B2 (en) * 2007-06-01 2015-01-06 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
EP2379720B1 (en) * 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
JP2013510576A (ja) * 2009-11-11 2013-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート ｉＰＳ細胞の生成および調節のための方法およびその組成物
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
WO2011157714A1 (en) * 2010-06-15 2011-12-22 ETH Zürich, ETH Transfer Pdms-based stretchable multi-electrode and chemotrode array for epidural and subdural neuronal recording, electrical stimulation and drug delivery
US8957042B2 (en) * 2012-03-07 2015-02-17 The Texas A&M University System Cancer treatment targeting non-coding RNA overexpression
CN102908344A (zh) * 2012-08-24 2013-02-06 海口市制药厂有限公司 一种含美罗培南的药物组合物及其制备方法和用途
US9314433B2 (en) * 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2014167464A1 (en) * 2013-04-08 2014-10-16 Sederma Production method of meristematic cells of plantago lanceolata, composition comprising said cells or their cellular extract, and cosmetic, nutraceutical and dermatological uses
CN109423517B (zh) * 2017-08-28 2022-08-05 中国医学科学院肿瘤医院 外泌体在肿瘤诊断、治疗和预后评估中的用途

Also Published As

Publication number Publication date
MX421795B (es) 2025-03-14
IL261884B (en) 2021-02-28
BR112018068986A2 (pt) 2019-01-22
IL261884A (en) 2018-10-31
US20190224193A1 (en) 2019-07-25
WO2017161387A1 (en) 2017-09-21
ZA201806128B (en) 2020-02-26
BR112018068986B1 (pt) 2023-03-21

Similar Documents

Publication Publication Date Title
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
MX2017014195A (es) Hidrogenacion de aceite de cannabis.
MX2019001286A (es) Composicion de cannabis.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
MX2018013240A (es) Composiciones antiirritantes sinergisticas de taurina y aloe.
BR112017025221A2 (pt) composições cosméticas compreendendo esclareolida
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2020002642A1 (es) Composición para modular genes responsables de las funciones generales de la piel, que comprende al menos un extracto vegetal de schinus terebinthifolius y cafeína (divisional de la solicitud 03354-2018)
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
MX2021003832A (es) Metodo y composicion para aliviar la fatiga y restaurar la energia.
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
AR096260A1 (es) Inhibidor de la corrosión de henna para un ácido en un pozo